EGFR and cancer: By definition, chemotherapy targets proliferating cells, so it is conceivable that, while the majority of cancer cells are inhibited by gefitinib, carboplatin and pemetrexed exert a stronger effect on the subpopulations of cells whose growth is not, or only poorly, affected by the EGFR-TKI.